Status:
COMPLETED
Risk Factors for Low Lymphocyte Count in Patients With Type 2 Diabetes
Lead Sponsor:
AstraZeneca
Collaborating Sponsors:
Bristol-Myers Squibb
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
40+ years
Brief Summary
The purpose of this study is to identify risk factors for low lymphocyte count among patients with type 2 diabetes who are treated with oral antidiabetic drugs.
Detailed Description
Involving a secondary analysis of data collected prospectively from a defined cohort, for the SAVOR trial.
Eligibility Criteria
Inclusion
- Enrolled in SAVOR
- Diagnosed with T2DM
- Baseline HbA1c ≥6.5% (based on the last measured and documented laboratory measurement within 6 months)
- Age 40 or older
- High risk for a cardiovascular event
Exclusion
- Not enrolled in SAVOR
- Current or previous treatment with DPP4 inhibitors and/or GLP-1 or incretin mimetics.
- Acute vascular event
- Pregnancy
- HIV/AIDS
- Severe autoimmune disease
- Current chronic steroid use
Key Trial Info
Start Date :
May 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2015
Estimated Enrollment :
16492 Patients enrolled
Trial Details
Trial ID
NCT01192659
Start Date
May 1 2010
End Date
December 1 2015
Last Update
December 1 2016
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.